S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
TSE:AKU

Akumin Stock Forecast, Price & News

C$4.40
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.37
Now: C$4.40▼
C$4.57
50-Day Range
C$3.72
MA: C$4.02▼
C$4.70
52-Week Range
C$1.75
Now: C$4.40▼
C$4.98
Volume21,372 shs
Average Volume66,066 shs
Market CapitalizationC$307.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Akumin Inc. provides outpatient diagnostic imaging services in the United States. As of December 31, 2019, the company operated 129 imaging centers located in Florida, Pennsylvania, Delaware, Georgia, Texas, Illinois, and Kansas. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders, and reduce unnecessary invasive procedures. The company provides a range of medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, radiology, and other diagnostic or interventional radiology procedures; and online medical bill payment services. Akumin Inc. is headquartered in Toronto, Canada.

Headlines

Akumin Inc. Announces Proposed Offering of Additional Senior Secured Notes
February 8, 2021 |  finance.yahoo.com
Akumin Enters into Settlement Agreement
February 1, 2021 |  finance.yahoo.com
Is There More Growth In Store For Akumin's (TSE:AKU) Returns On Capital?
January 12, 2021 |  finance.yahoo.com
Vancouver Dentist Announces a Breath of Fresh Air for Smile City Square Dental Patients
December 9, 2020 |  finance.yahoo.com
Is Akumin Inc. (AKU) A Good Stock To Buy?
November 26, 2020 |  finance.yahoo.com
Akumin Inc. (AKU.TO)
November 12, 2020 |  finance.yahoo.com
Akumin Inc. Announces Third Quarter 2020 Financial Results
November 12, 2020 |  finance.yahoo.com
Akumin Inc. Announces Completion of Offering of Senior Secured Notes
November 2, 2020 |  finance.yahoo.com
Akumin to Host Third Quarter 2020 Financial Results Call on November 12, 2020
November 2, 2020 |  finance.yahoo.com
Akumin Inc. Announces Pricing of Offering of Senior Secured Notes
October 23, 2020 |  finance.yahoo.com
Akumin Inc. Announces Proposed Offering of Senior Secured Notes
October 20, 2020 |  finance.yahoo.com
Optimistic Investors Push Akumin Inc. (TSE:AKU) Shares Up 29% But Growth Is Lacking
September 18, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:AKU
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.akumin.com
Phone416-613-1391
Employees1,737
Year FoundedN/A

Debt

Debt-to-Equity Ratio360.05
Current Ratio2.22
Quick Ratio2.17

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesC$269.04 million
Price / Sales1.14
Cash FlowC$0.39 per share
Price / Cash Flow11.28
Book ValueC$1.95 per share
Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares69,841,000
Market CapC$307.30 million
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.73 out of 5 stars

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$4.40
0.00 (0.00 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKU News and Ratings via Email

Sign-up to receive the latest news and ratings for AKU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akumin (TSE:AKU) Frequently Asked Questions

Is Akumin a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akumin in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Akumin stock.
View analyst ratings for Akumin or view top-rated stocks.

What stocks does MarketBeat like better than Akumin?

Wall Street analysts have given Akumin a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akumin wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Akumin's next earnings date?

Akumin is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Akumin.

How has Akumin's stock price been impacted by Coronavirus?

Akumin's stock was trading at C$4.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AKU stock has increased by 9.7% and is now trading at C$4.40.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AKU?

2 Wall Street analysts have issued 1-year price objectives for Akumin's stock. Their forecasts range from C$3.25 to C$5.25. On average, they anticipate Akumin's share price to reach C$4.25 in the next year. This suggests that the stock has a possible downside of 3.4%.
View analysts' price targets for Akumin or view top-rated stocks among Wall Street analysts.

Who are Akumin's key executives?

Akumin's management team includes the following people:
  • Mr. Riadh Zine-El-Abidine, Pres, CEO & Director (Age 49, Pay $1.26M)
  • Mr. Mohammad Saleem, CFO & Corp. Sec.
  • Mr. Rohit Navani, Exec. VP & COO
  • Mr. Matthew Cameron, Sr. VP & Gen. Counsel
  • Mr. Christopher Fitzgerald, Chief Revenue Officer
  • Darren Speed, Chief Compliance Officer
  • Karen Moore, VP of HR
  • Ms. Laura Kassa, Sr. VP
  • Adam Fabian, Corp. Controller
  • Mr. Kevin G. Johnson, CEO & Pres of Advanced Diagnostic Group, LLC

Who are some of Akumin's key competitors?

Some companies that are related to Akumin include MaxCyte (MXCT), Lucira Health (LHDX), Renalytix AI plc (RENX.L) (RENX), Profound Medical Corp. (PRN.TO) (PRN), Biodesix (BDSX), Oncimmune Holdings plc (ONC.L) (ONC), Yourgene Health (YGEN), LexaGene (LXG), genedrive (GDR), Relay Medical (RYMDF), Global WholeHealth Partners (GWHP), SQI Diagnostics Inc. (SQD.V) (SQD), Sernova Corp. (SVA.V) (SVA), Deepmatter Group (DMTR) and GeneNews (GEN).
View all of AKU's competitors.

What other stocks do shareholders of Akumin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akumin investors own include AltaGas (ALA), Alimentation Couche-Tard (ATD.B), Brookfield Asset Management (BAM.A), Brookfield Property Partners (BPY.UN), Cargojet Inc. (CJT.TO) (CJT), Canadian National Railway (CNR), Dollarama (DOL), Enbridge (ENB), Héroux-Devtek Inc. (HRX.TO) (HRX) and Inter Pipeline (IPL).

What is Akumin's stock symbol?

Akumin trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AKU."

How do I buy shares of Akumin?

Shares of AKU and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Akumin's stock price today?

One share of AKU stock can currently be purchased for approximately C$4.40.

How much money does Akumin make?

Akumin has a market capitalization of C$307.30 million and generates C$269.04 million in revenue each year.

How many employees does Akumin have?

Akumin employs 1,737 workers across the globe.

What is Akumin's official website?

The official website for Akumin is www.akumin.com.

How can I contact Akumin?

The company can be reached via phone at 416-613-1391.


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.